Systematic Financial Management LP Raises Position in Integra LifeSciences Holdings Corporation $IART

Systematic Financial Management LP raised its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 4.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,108,599 shares of the life sciences company’s stock after buying an additional 48,094 shares during the period. Systematic Financial Management LP owned approximately 1.42% of Integra LifeSciences worth $13,769,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Rubric Capital Management LP boosted its position in Integra LifeSciences by 4.1% in the 3rd quarter. Rubric Capital Management LP now owns 7,653,934 shares of the life sciences company’s stock valued at $109,681,000 after buying an additional 300,000 shares during the period. Dimensional Fund Advisors LP boosted its position in Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after buying an additional 267,134 shares during the period. Paradigm Capital Management Inc. NY boosted its position in Integra LifeSciences by 57.5% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock valued at $26,767,000 after buying an additional 796,300 shares during the period. Goldman Sachs Group Inc. boosted its position in Integra LifeSciences by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after buying an additional 35,790 shares during the period. Finally, Soleus Capital Management L.P. boosted its position in Integra LifeSciences by 29.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company’s stock valued at $17,029,000 after buying an additional 315,614 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on IART. Wells Fargo & Company raised their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Truist Financial reduced their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Citigroup raised their price objective on shares of Integra LifeSciences from $9.00 to $11.00 and gave the company a “sell” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Three equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $12.75.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $15.10 on Monday. Integra LifeSciences Holdings Corporation has a 12 month low of $8.70 and a 12 month high of $16.49. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The business has a 50 day simple moving average of $11.10 and a 200-day simple moving average of $11.70. The stock has a market capitalization of $1.17 billion, a PE ratio of -2.34, a price-to-earnings-growth ratio of 1.05 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. During the same quarter in the prior year, the business earned $0.41 earnings per share. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.